![Vanessa Jacoby](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Vanessa Jacoby
Directeur/Bestuurslid bij
SONOMA PHARMACEUTICALS, INC.
Profiel
Vanessa Lusitano Jacoby is currently an Independent Director at Sonoma Pharmaceuticals, Inc. since 2026 and Chief Financial & Business Officer at Quanta Therapeutics, Inc. Former roles include Vice President-Finance at PharmAkea, Inc. from 2014 to 2019, Senior Manager-Finance at Artes Medical, Inc. in 2008, Accounting Director & Controller at BrainCells, Inc., Performance Analyst at Nicholas-Applegate Capital Management, Auditor at Ernst & Young LLP, and Revenue Manager at Diversa Corp.
Education includes an MBA from National University conferred in 2003 and an undergraduate degree from Fundação Armando Alvares Penteado conferred in 1998.
Actieve functies van Vanessa Jacoby
| Bedrijven | Functie | Begin |
|---|---|---|
| SONOMA PHARMACEUTICALS, INC. | Directeur/Bestuurslid | 28-01-2026 |
Quanta Therapeutics, Inc.
 Quanta Therapeutics, Inc. BiotechnologyHealth Technology Develops allosteric inhibitors for RAS-driven cancers | Financieel Directeur/CFO | - |
Eerdere bekende functies van Vanessa Jacoby
| Bedrijven | Functie | Einde |
|---|---|---|
PharmAkea, Inc.
 PharmAkea, Inc. Pharmaceuticals: MajorHealth Technology Develops small molecule drug candidates against protein targets involved in fibroproliferative diseases | Financieel Directeur/CFO | 01-01-2019 |
Artes Medical, Inc.
 Artes Medical, Inc. Pharmaceuticals: MajorHealth Technology Develops and manufactures, commercializes of injectable aesthetic products for dermatology and plastic surgery markets | Corporate Officer/Principal | 01-01-2008 |
Ernst & Young LLP
 Ernst & Young LLP Miscellaneous Commercial ServicesCommercial Services Provides assurance, auditing, tax, legal, technology and consulting & managed services | Corporate Officer/Principal | - |
Nicholas-Applegate Capital Management
 Nicholas-Applegate Capital Management Investment ManagersFinance Nicholas-Applegate Capital Management employs a forward-thinking, change-focused investment philosophy to create domestic and international portfolios across fundamental and systematic equity, income and growth strategies. The firm's investment approach seeks to identify points of inflection that could lead to strong price appreciation and to invest in a timely manner to maximize return potential. The firm's range of investment strategies include domestic, global, international and specialty portfolios. Each portfolio follows one of two approaches: traditional or model-driven (systematic). Nicholas-Applegate tends to invest in the stocks of companies in the electronic technology, health technology, technology services, consumer non-durables and finance sectors. The firm invests globally, across all market-caps. Nicholas-Applegate maintains a medium turnover rate. | Corporate Officer/Principal | - |
Diversa Corp.
 Diversa Corp. Miscellaneous Commercial ServicesCommercial Services Researches and develops genomic tools and biological technology for the agricultural industry | Corporate Officer/Principal | - |
Opleiding van Vanessa Jacoby
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
58
Eerstegraads connecties
10
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Bedrijven in privébezit | 10 |
|---|---|
Nicholas-Applegate Capital Management
Nicholas-Applegate Capital Management Investment ManagersFinance Nicholas-Applegate Capital Management employs a forward-thinking, change-focused investment philosophy to create domestic and international portfolios across fundamental and systematic equity, income and growth strategies. The firm's investment approach seeks to identify points of inflection that could lead to strong price appreciation and to invest in a timely manner to maximize return potential. The firm's range of investment strategies include domestic, global, international and specialty portfolios. Each portfolio follows one of two approaches: traditional or model-driven (systematic). Nicholas-Applegate tends to invest in the stocks of companies in the electronic technology, health technology, technology services, consumer non-durables and finance sectors. The firm invests globally, across all market-caps. Nicholas-Applegate maintains a medium turnover rate. | Finance |
Ernst & Young LLP
Ernst & Young LLP Miscellaneous Commercial ServicesCommercial Services Provides assurance, auditing, tax, legal, technology and consulting & managed services | Commercial Services |
Diversa Corp.
Diversa Corp. Miscellaneous Commercial ServicesCommercial Services Researches and develops genomic tools and biological technology for the agricultural industry | Commercial Services |
Sonoma Pharmaceuticals, Inc.
 Sonoma Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops, manufactures and sells stabilized hypochlorous acid | Health Technology |
BrainCells, Inc.
 BrainCells, Inc. Pharmaceuticals: MajorHealth Technology Discovers and develops drugs | Health Technology |
PharmAkea, Inc.
PharmAkea, Inc. Pharmaceuticals: MajorHealth Technology Develops small molecule drug candidates against protein targets involved in fibroproliferative diseases | Health Technology |
Artes Medical, Inc.
Artes Medical, Inc. Pharmaceuticals: MajorHealth Technology Develops and manufactures, commercializes of injectable aesthetic products for dermatology and plastic surgery markets | Health Technology |
National University
 National University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Fundação Armando Alvares Penteado
 Fundação Armando Alvares Penteado Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Quanta Therapeutics, Inc.
Quanta Therapeutics, Inc. BiotechnologyHealth Technology Develops allosteric inhibitors for RAS-driven cancers | Health Technology |
